| Project/Area Number |
04558014
|
|---|
| Research Category |
Grant-in-Aid for Developmental Scientific Research (B)
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Laboratory animal science
|
|---|
| Research Institution | Tokyo Metropolitan Institute for Medical Science |
|---|
Principal Investigator |
MIYASAKA Masayuki Tokyo Metropolitan Institute of Medical Science, Dept.Immunol., Head, 免疫研究部門, 研究員 (50064613)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
NAWA Yukifumi Miyazaki University Medical School Dept.Parasitol., Professor, 寄生虫学教室, 教授 (10040172)
UEYAMA Yoshihito Tokai University Medical School Dept.Pathol., Associate Professor, 病理学教室, 助教授 (30072408)
URANO Kouji Institute for Experimental Animals Research Scientist, 研究員 (80213510)
KITAMURA Fujiko TMIMS, Dept.Immunol., Research Member, 免疫研究部門, 研究員 (90124453)
TANAKA Toshiyuki TMIMS, Dept.Immunol., Research Member, 免疫研究部門, 研究員 (30217054)
|
|---|
| Project Period (FY) |
1992 – 1993
|
| Project Status |
Completed (Fiscal Year 1993)
|
| Budget Amount *help |
¥7,400,000 (Direct Cost: ¥7,400,000)
Fiscal Year 1993: ¥2,500,000 (Direct Cost: ¥2,500,000)
Fiscal Year 1992: ¥4,900,000 (Direct Cost: ¥4,900,000)
|
|---|
| Keywords | IL-2 receptor beta chain / NK cell / SCID mouse / SCID-Hu / IL-1受容体beta鎖 / 腫瘍 / 移植 / IL-2受容体 / マウス |
|---|
| Research Abstract |
By takeing advantage of the fact that natural killer (NK) cells can be eliminated specifically for long-term in vivo by a single i.p. injection of monoclonal antibody against IL-2 receptor beta chain (anti-IL-2Rbeta), we attempted to generate a mouss model in which various types of human cells can be readily transplanted. We found that injection of the anti-IL-2Rbeta into SCID mice induces long-term elimination of NK cells, thus generating T-, B- and NK-deficient mice. ATL cells that do not normally grow in untreated SCID mice did grow well in such antibody-treated NK-deficient SCID mice, raising an interesting possibility that this in vivo model can be used for screening and testing the efficacy of anti-ATL drug candidates. This antibody may be also be beneficial for generation of SCID-Hu.
|
